CompletedPhase 4ketamine

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT ID

NCT00419003

Target Enrollment

26 participants

Start Date

2006-12

Est. Completion

2008-09

About This Study

This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine.

Conditions Studied

Major Depression

Interventions

•Lamotrigine
•Ketamine
•Riluzole

Eligibility

Age:21 Years - 70 Years

Healthy Volunteers:No

View full eligibility criteria

Inclusion Criteria:

1. Male or female patients, 21- 70 years of age
2. Subjects have a history of at least one previous episode of depression prior to the current episode (recurrent major depressive disorder) or have chronic major depressive disorder (at least two years' duration)
3. Subjects have not responded to an adequate trial of one antidepressant in the current episode

Exclusion Criteria:

1. Female subjects who are either pregnant or nursing
2. Serious, unstable illnesses
3. Any previous use or treatment with ketamine, or riluzole
4. Past intolerance to lamotrigine, including drug rash

Study Locations (1)

Mount Sinai School of Medicine